Pasithea Therapeutics Corp Stock Performance
| KTTA Stock | USD 3.18 0.01 0.31% |
The company holds a Beta of 0.57, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pasithea Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pasithea Therapeutics is expected to be smaller as well. At this point, Pasithea Therapeutics has a negative expected return of -0.22%. Please make sure to check Pasithea Therapeutics' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Pasithea Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.25 | Five Day Return (5.56) | Year To Date Return (59.88) | Ten Year Return (95.46) | All Time Return (95.46) |
Last Split Factor 1:20 | Last Split Date 2024-01-02 |
1 | Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board | 09/03/2024 |
2 | Acquisition by Tiago Marques of 5000 shares of Pasithea Therapeutics at 1.0 subject to Rule 16b-3 | 09/13/2024 |
3 | Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic , and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-00... | 09/26/2024 |
4 | Pasithea Therapeutics Corp. Short Interest Down 90.7 percent in September | 09/27/2024 |
5 | Acquisition by Novak Alfred J of 5000 shares of Pasithea Therapeutics at 8.13 subject to Rule 16b-3 | 10/17/2024 |
6 | Acquisition by Dumesnil Simon of 10000 shares of Pasithea Therapeutics at 1.07 subject to Rule 16b-3 | 10/28/2024 |
7 | Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ... | 11/20/2024 |
| Begin Period Cash Flow | 33.1 M |
Pasithea |
Pasithea Therapeutics Relative Risk vs. Return Landscape
If you would invest 465.00 in Pasithea Therapeutics Corp on August 23, 2024 and sell it today you would lose (147.00) from holding Pasithea Therapeutics Corp or give up 31.61% of portfolio value over 90 days. Pasithea Therapeutics Corp is currently does not generate positive expected returns and assumes 9.3606% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than Pasithea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pasithea Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pasithea Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pasithea Therapeutics Corp, and traders can use it to determine the average amount a Pasithea Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KTTA |
Estimated Market Risk
| 9.36 actual daily | 83 83% of assets are less volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pasithea Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pasithea Therapeutics by adding Pasithea Therapeutics to a well-diversified portfolio.
Pasithea Therapeutics Fundamentals Growth
Pasithea Stock prices reflect investors' perceptions of the future prospects and financial health of Pasithea Therapeutics, and Pasithea Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pasithea Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | (7.94 M) | ||||
| Shares Outstanding | 1.27 M | ||||
| Price To Book | 0.23 X | ||||
| Price To Sales | 42.15 X | ||||
| Revenue | 486.56 K | ||||
| Gross Profit | (2.21 K) | ||||
| EBITDA | (15.33 M) | ||||
| Net Income | (15.51 M) | ||||
| Cash And Equivalents | 47.94 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 81.68 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 51.17 X | ||||
| Book Value Per Share | 22.46 X | ||||
| Cash Flow From Operations | (13.43 K) | ||||
| Earnings Per Share | (14.79) X | ||||
| Market Capitalization | 4.04 M | ||||
| Total Asset | 26.12 M | ||||
| Retained Earnings | (35.32 M) | ||||
| Working Capital | 14.06 M | ||||
About Pasithea Therapeutics Performance
By analyzing Pasithea Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Pasithea Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pasithea Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pasithea Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.90) | |
| Return On Capital Employed | (0.68) | (0.71) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about Pasithea Therapeutics performance evaluation
Checking the ongoing alerts about Pasithea Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pasithea Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pasithea Therapeutics generated a negative expected return over the last 90 days | |
| Pasithea Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 486.56 K. Net Loss for the year was (15.51 M) with loss before overhead, payroll, taxes, and interest of (2.21 K). | |
| Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.43 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ... |
- Analyzing Pasithea Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pasithea Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pasithea Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pasithea Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pasithea Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pasithea Therapeutics' stock. These opinions can provide insight into Pasithea Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |